Related Experiment Video
Updated: Feb 7, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
Long-term clinical outcomes of patients with hematologically unexplained cytopenia after routine assessment: A single
Morten Munk Johansen1, Michael Asger Andersen1, Kirsten Grønbaek1
1Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Insights
Patients with unexplained cytopenia (UC) face a significantly higher risk of developing hematological diseases, cancers, and liver or rheumatic conditions. This condition also leads to increased mortality, particularly in older adults.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Background:
- Unexplained cytopenia (UC) is a condition characterized by low blood cell counts without a clear cause.
- Long-term outcomes for patients with UC are not well-established.
- Identifying risks associated with UC is crucial for patient management and prognosis.
Purpose of the Study:
- To investigate the long-term risk of malignant hematological diseases, cancers, and other significant non-malignant conditions in patients with UC.
- To assess the overall mortality rates in patients diagnosed with UC compared to a matched control population.
Main Methods:
- A cohort of 221 patients with UC was identified from 1820 referrals to a hematology outpatient clinic.
- Registry linkage was used to obtain ICD-10 diagnoses and survival data.
- Cumulative incidences and hazard ratios for mortality were calculated and compared to a control group, adjusting for relevant factors.
Main Results:
- Patients with UC showed a 5-year cumulative incidence of malignant hematological disease of 8.91%, significantly higher than controls (0.93%).
- Increased incidences of cancer, liver disease, and rheumatic disease were observed in the UC cohort.
- Adjusted analysis revealed a 1.43 hazard ratio for all-cause mortality in UC patients compared to controls, with higher risks noted in those aged 50 and above.
Conclusions:
- Unexplained cytopenia is associated with a substantially elevated risk of developing hematological malignancies, various cancers, and other serious conditions.
- Patients with UC experience increased mortality compared to the general population.
- The findings underscore the importance of vigilant monitoring and management for individuals diagnosed with unexplained cytopenia, especially older patients.
Objective:
We investigated mortality and long-term development of malignant hematological disease, cancer, liver-, renal-, and rheumatic disease in patients with unexplained cytopenia (UC).
Methods:
We screened all patients referred to the outpatient clinic at the Department of Hematology, Rigshospitalet, Copenhagen, with a suspected myeloid neoplasm from June 2009 to the end of 2012. Through registry linkage, we obtained information on hospital-based ICD-10 diagnoses and survival. We estimated cumulative incidences of disease and hazard ratios of all-cause mortality using the Aalen-Johansen estimator and Cox regression. We compared incidences and mortality with a control cohort.
Results:
Among 1820 referrals, 221 had UC. The UC group had a 5-year cumulative incidence of malignant hematological disease of 8.91% (CI 95%: 4.98-12.84) compared to 0.93(CI 95%: 0.32-1.55) in the matched controls. In addition, UC patients had higher incidences of cancer, liver, and rheumatic disease. Mortality was higher in UC patients compared to the matched controls with a HR of 1.43 [P = 0.038, CI 95%: 1.02-2.00] adjusted for comorbidity, sex, and age. Most of the mortality and morbidity were ascribed to patients 50 years or older.
Conclusions:
Unexplained cytopenia patients had a higher incidence of malignant hematological-, cancer-, liver-, and rheumatic disease and increased mortality compared to the general population.
Related Concept Videos
Patient-centered Care
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Angina III: Clinical Manifestations and Assessment
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Predicting Reaction Outcomes
Center of Gravity

